Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin, Francesco Bandello, Justus G Garweg, Lutz L Hansen, Simon P Harding, Michael Larsen, Paul Mitchell, Dianne Sharp, U E K Wolf-Schnurrbusch, Margarita Gekkieva, Andreas Weichselberger, Sebastian Wolf

642 Citationer (Scopus)

Abstract

The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.
OriginalsprogEngelsk
TidsskriftDiabetes Care
Vol/bind33
Udgave nummer11
Sider (fra-til)2399-405
Antal sider7
ISSN0149-5992
DOI
StatusUdgivet - 1 nov. 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study'. Sammen danner de et unikt fingeraftryk.

Citationsformater